Market Intelligence, Preclinical Progress, and High-Purity Reagents for Emerging Oncology, Fibrosis, and Inflammatory Disease Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SERPINA2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SERPINA2 Recombinant Protein (WT & Custom Mutants, including variants V1 and V3) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). Theoretical MW provided. |
View SERPINA2 Products |
| Gene Delivery | SERPINA2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression studies. Puromycin selection. |
View SERPINA2 Products |
| Benchmark Ab | Anti-SERPINA2 Control Antibody Recombinant monoclonal for detection, Western Blot, immunoprecipitation. Highly specific, validated against SERPINA1 and SERPINA3. |
View SERPINA2 Products |
| Validator | SERPINA2 siRNA Set For knockdown verification, specificity controls, and target engagement studies. |
View SERPINA2 Products |
| Related Target A | SERPINA1 (Alpha-1 Antitrypsin) Closest paralog; essential for serpin family counter-screening and structural comparison. |
View SERPINA1 Products |
| Related Target B | SERPINA3 Complementary serpin for pathway network analysis and off-target assessment. |
View SERPINA3 Products |
| Related Target C | ELANE (Neutrophil Elastase) Classic downstream interacting protease for functional inhibition assays. |
View ELANE Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High Homology Cross-Reactivity (vs SERPINA1 and SERPINA3) | Homolog panel proteins (SERPINA1, SERPINA3) available, strictly verified by mass spec and sequence analysis. Highly specific anti-SERPINA2 antibody validated against both. |
| Proper Protein Folding & Secretion / Lack of sequence-confirmed antigen | HEK293-expressed SERPINA2 with native glycosylation; Sequence Verified; Theoretical MW provided; >95% purity; Endotoxin <1EU/ug. |
| Lack of Reliable Controls for functional studies | Recombinant positive control antibodies and validated siRNA sets included for assay standardization and knockdown verification. |
| Stable overexpression cell line generation | Lentivirus particles with full-length ORF (including WT and custom mutant variants); Puromycin selection; suitable for Flow Cytometry and Western Blot. |
| Need for variant-specific reagents | TarMart offers custom mutant proteins covering reported variants (e.g., rs2089497656 and rs2089497643) to enable variant-functional and biomarker studies. |
Global Clinical Landscape & Future Outlook
SERPINA2 remains an emerging target in the serpin superfamily, historically under-explored and sometimes annotated as a pseudogene. Recent transcriptomic and proteomic evidence, however, confirms its expression in specific tumor microenvironments, fibrotic tissue, and during inflammatory responses. The race for targeting novel serpin family members is intensifying as the limitations of broad-spectrum protease inhibitors become apparent. Current R&D is concentrated in academic and preclinical settings, focusing on target validation, biomarker development, and functional characterization. Known mutations (e.g., in alleles V1 and V3, dbSNP rs2089497656 and rs2089497643) provide a foundation for variant-specific studies, linking SERPINA2 to differential protease inhibition and disease susceptibility. As the field moves from gene annotation to functional validation, demand for high-specificity reagents is expected to grow, positioning SERPINA2 as a compelling target in oncology, fibrosis, and immune diseases.
Live SERPINA2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Early-stage Biotech, Preclinical Discovery | Oncology (TME), Fibrosis, Immune diseases | Epitope selectivity assay vs paralogs; need high-purity antigens and homolog panel |
| siRNA / ASO | Preclinical Gene Therapy Firms, Academic Labs | Inflammatory diseases, oncogenic signaling | Knockdown validation with sequence-verified siRNA |
| Recombinant Protein Therapy / Enzymology | Translational Research Labs, Academic Consortia | Enzyme replacement, modulator, inflammation | Pharmacokinetic profiling; endotoxin-controlled (<1EU/ug) proteins for in vivo studies |
| Gene Therapy / ORF | Early-stage Research | Rare disease models, functional studies | Stable cell line generation via lentivirus; sequence-verified ORF including mutants |
Key Mutations & Variants
Publicly reported variants in SERPINA2 include mutations in alleles V1 and V3 (dbSNP rs2089497656) and in allele V1 (rs2089497643). These variations may affect the reactive center loop or protein stability, potentially altering protease inhibition specificity. TarMart provides recombinant proteins and ORF constructs encompassing these mutants to facilitate functional characterization and biomarker development.